months in whom lumbar puncture is performed, even if they do not have pleocytosis. The use of molecular techniques could potentially contribute to reducing the number of days of unnecessary antibiotic therapy.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References


Marta Seoane Rodríguez, Angelina Cañizares Castellanos, Alejandro Avila-Alvarez

a Unidad de Neonatología, Servicio de Pediatría, Complejo Hospitalario Universitario de A Coruña (CHUC), Sergas, A Coruña, Spain
b Servicio de Microbiología, Complejo Hospitalario Universitario de A Coruña (CHUC), Sergas, A Coruña, Spain

* Corresponding author.
E-mail address: alejandro.avila.neonatologia@gmail.com
(A. Avila-Alvarez).

2529-993X/ © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV

Hepatitis aguda fulminante por virus B durante el tratamiento del virus de la hepatitis C con antivirales de acción directa en paciente infectado con VIH

Co-infection with hepatitis C (HCV) and B (HBV) viruses is common in clinical practice. We report a case of fulminant hepatic failure as a consequence of reactivation of HBV in a patient with human immunodeficiency virus (HIV) after HCV treatment.

This was a 53-year-old man diagnosed in 1998 with HIV infection following detection of pulmonary tuberculosis, with a good current response to antiretroviral therapy. In addition, he had chronic HCV genotype 1a infection and a history of previous HBV infection with positive IgG (anti-HBc IgG) core antibody, negative surface antigen (HBsAg) and antibodies (anti-HBs) and undetectable levels of HBV DNA, prior to initiation of treatment with direct-acting antivirals (DAA).

For his HIV infection, the patient had previously followed several treatment regimens with multiple failures and development of resistance. In 2011, he was prescribed treatment with tenofovir (TDF), abacavir and ritonavir-boosted atazanavir. The TDF was subsequently withdrawn after a slight worsening of his renal function, and the treatment was simplified to darunavir/cobicistat monotherapy. Since then, his viral load has been undetectable and his CD4 T-cell lymphocytes 500–800/mm3 (CD4 T lymphocytes 800/mm3 at most recent testing, prior to starting HCV treatment).

In October 2013, the patient started treatment for HCV according to the regimen pegylated interferon alpha-2a 180 μg, one weekly injection, and ribavirin 1000 mg daily (3–0–2), resulting in a 3-log decrease in HCV viral load by week 4 of treatment. The idea of adding first-generation direct-acting antivirals (telaprevir) was proposed, but the patient refused to continue treatment because of poor tolerance to interferon.

In December 2015, his HCV viral load was 2,181,330 IU/ml with a liver stiffness measurement of 12 kPa. Since we already had DAA, he was started on treatment with sofosbuvir and ledipasvir for 12 weeks. In week 2, his viral load had dropped to 284.51 IU/ml, by week 4 it was down to 30.45 IU/ml and by week 8 it was less than 15 IU/ml, with a sustained viral response at week 4 post-treatment.

A month later, the patient consulted with abdominal pain, nausea and jaundice, with total bilirubin 10.98 mg/dl, direct bilirubin 8.75 mg/dl, GOT 1025.40 IU/l, GPT 642 IU/l and INR 1.30. An HBV viral load of 6,193,455.96 IU/ml was found, with positive HBsAg, anti-HBc IgM and HBeAg serology. His HCV viral load remained undetectable, and hepatitis D virus was negative. We were therefore dealing with acute hepatitis caused by HBV.

The patient was started on treatment with entecavir (TDF had already been discontinued due to impaired renal function); however, he made poor progress and was included in a pre-liver transplant study. Despite the treatment, the patient became worse and was transferred to the Intensive Care Unit, where he continued to deteriorate and died as a result of acute liver failure.

The patient’s HBV viral load was requested from samples stored during the HCV treatment; it was undetectable at the start of treatment and at week 2, but progressively increased to 98.80 IU/ml after 8 weeks of treatment and then to 82,700 IU/ml at week 4 post-treatment (Fig. 1).

The risk of reactivation of HBV in the context of immunosuppressive therapy is well known. However, several cases of HBV reactivation following DAA treatment in HCV–HBV co-infected patients have been reported, and although most have had no clinical repercussions and a good response to nucleotide/nucleoside analogue treatment, there was one 59-year-old patient with genotype 1b who developed acute fulminant HBV hepatitis in week 11 of treatment and had to have a liver transplant.

In HCV–HBV co-infected patients, HBV DNA is usually low or undetectable, although it can fluctuate, with HCV being the main cause of chronic liver activity. Different theories have been put forward to explain the inhibition of HBV replication in co-infected patients. The first is that there seems to be a direct interaction between the two viruses, with HCV inhibiting HBV replication, but...
Spondylodiscitis due to *Aerococcus urinae* infection in an elderly immunocompetent patient

*Espondilodiscitis debida a Aerococcus urinae en paciente anciano inmunocompetente*

In January 2015, a 79-year-old man visited the emergency room complaining of increasingly severe low lumbar pain, which he had had during the previous 2 weeks. The patient presented leg pain, originating from the buttock region and radiating into the whole thigh, leg and foot. He was apyretic and had lost 18 kg. He had no particular antecedents except for a prostatic adenoma. The patient was hospitalized to control pain. Three days after admission to hospital, blood and urine specimens were taken for culture and magnetic resonance imaging (MRI) was performed. MRI revealed increased signal intensity at the L4-L5 position, compatible with a diagnosis of spondylodiscitis at this location (Fig. 1). Blood cultures were negative, although a urine culture yielded growth of *Enterococcus faecalis*. The patient was initially treated with intravenous ampicillin and gentamicin, assuming that *E. faecalis* was responsible for the discitis. Twelve present, we are still uncertain about how to optimally manage these situations. The therapy is possible increase in the space available for replication of the B virus after HCV treatment. The most accepted theory for the moment, however, is that chronic HCV replication produces an immune status in the body which helps to control HBV replication, but that this is interrupted by treatment with DAA.

In conclusion, this is the first reported case of fulminating HBV-related liver failure in the context of treatment with the new DAAAs in a patient with HIV. The patient had been pre-treated with IFN for 4 weeks with no evidence of reactivation of HBV, so it might be argued that in view of their action against HBV, IFN-based therapies might be safer in this regard, at the expense of more adverse effects. In addition, there was no evidence of reactivation when TDF was withdrawn, which gives more weight to a relationship between the DAA treatment and the reactivation of HBV. We do not know whether the HBV reactivation or poor clinical outcome might be related to HIV infection, particularly when patients are not on 3TC/TDF treatment. Moreover, it must be taken into account a large number of co-infected patients are treated with nucleoside/nucleotide analogues, which could prevent the reactivation of HBV. Also, our patient had no anti-HBs, so it would be interesting to assess the isolated risk in people with negative anti-HBs. At

References


Maria Paniagua-García*, Inmaculada López-Hernández, Felipe Fernández-Cuenca, María José Ríos-Villegas

Unidad de Gestión Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain

*Corresponding author.

E-mail address: maria.paniagua89@gmail.com (M. Paniagua-García).

2529-993X/ © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Fig. 1. Viral load of HCV and HBV after start of treatment and transaminase levels (AST).

http://dx.doi.org/10.1016/j.eimc.2017.02.005